Is Bristol-Myers Squibb Company (BMY) Stock at Risk From Proposed Medicare Drug Price Negotiation Updates?

We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Bristol-Myers Squibb Company (NYSE:BMY) is one of the best low-priced pharma stocks on this list.

TheFly reported on June 15 that RBC Capital analyst Trung Huynh noted that the proposed changes to the Medicare Drug Price Negotiation Program could introduce potential risks for companies, including Bristol-Myers Squibb Company (NYSE:BMY) and several others. The proposal would make the program permanent starting in 2029 and introduce stricter requirements around fixed-combination lifecycle strategies. However, the analyst highlighted that legal challenges, regulatory exemptions, and diversified product portfolios may reduce the overall impact on these companies.

Is Bristol-Myers Squibb Company (BMY) Stock at Risk From Proposed Medicare Drug Price Negotiation Updates?

In a separate regulatory update on June 1, BMY announced that the FDA accepted its supplemental New Drug Application for Camzyos as a potential treatment for adolescents with symptomatic obstructive hypertrophic cardiomyopathy. The application received Priority Review status, with the FDA assigning a PDUFA target action date of September 30, 2026. If approved, Camzyos would become the first cardiac myosin inhibitor available for adolescent patients with oHCM. The therapy is currently approved for adults with symptomatic NYHA class II-III oHCM to improve symptoms and functional capacity, with use reported among thousands of healthcare providers and patients across the U.S.

Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical company developing innovative medicines, including small molecules, biologics, and CAR-T therapies for cancer, cardiovascular, and immune-related diseases.

While we acknowledge the risk and potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1